摘要
目的观察选择性环氧化酶-2(COX-2)抑制药塞来昔布、罗非昔布对人骨肉瘤细胞株(HOS-8603)、肺癌细胞株(A-549)的作用以及罗非昔布、塞来昔布对两种细胞抑制效应的比较。方法MTT法测定体外培养的细胞株HOS-8603、A-549对不同浓度的罗非昔布和塞来昔布的敏感性,流式细胞仪分析细胞增殖周期的影响及凋亡。结果塞来昔布、罗非昔布均可明显抑制HOS-8603、A-549细胞的生长(P<0.05),抑制效应呈现浓度依赖型和时间依赖型。HOS-8603和A-549细胞分裂阻滞在G2/M期,出现凋亡峰,塞来昔布对HOS-8603的作用强于罗非昔布。结论COX-2抑制药塞来昔布尼罗非昔布对骨肉瘤细胞、肺癌细胞的生长有抑制作用,有望成为抗肿瘤新药。
Objective To compare the effects of two cyclooxygenase-2 inhibitors,celecoxib and rofecoxib on the growth of human osteosarcoma (HOS-8603) and lung cancer cell (A-549) lines. Methods The anti-proliferation effects were determined by methabenzthiazuron (MTT) method. The cell growing cycle and the cell apoptosis were analyzed by flow cytometry. Results Cyclooxygenase-2 inhibitors, celecoxib and rofecoxib had inhibitory and apoptosis-inducting effect on the growth of the two tumor cell lines. The inhibitions of celecoxib and rofecoxib to the two tumor cell lines were dose-dependent and time-dependent. The cells treated with the two drugs showed a G_2/M arrest which was the peak time of apoptosis. There was a significant difference between rofecoxib and celecoxib groups ( P <0.05). And celecoxib had a stronger inhibition to HOS-8603 than rofecoxib. Conclusion Cyclooxygenase-2 inhibitors, celecoxib and rofecoxib have significant effect on the growth of the two tumor cell lines, and may become useful medicines in tumor treatment.
出处
《医药导报》
CAS
2005年第7期559-562,共4页
Herald of Medicine
基金
湖北省科技攻关计划基金资助课题(基金编号:2004AA304B08)
关键词
环氧化酶-2抑制药
骨肉瘤
肺癌
细胞培养
Cyclooxygenase-2 inhibitor
Osteosarcoma
Lung cancer
Cell culture
